Tumors with AR T878X and/or H875Y mutations and excluding AR L702H mutations and AR-V7 splice variants Tumors with wild-type AR or AR alterations other than T878X, H875Y, L702H, AR-V7 Tumors with AR L702...
an AR-targeted PROTAC that discards the peptidic vestiges of the earlier PROTACs (compare8to structures1–7) [73]. Here, the removal of peptidic vestiges was enabled by the discovery of imidazoline inhibitors of the E3-ligase Mdm2 [74]. Structurally,8employs this imidazoline ligand of Mdm2 as...